Literature DB >> 8937669

Suspected drug eruption in seven dogs during administration of flucytosine.

R Malik1, C Medeiros, D I Wigney, D N Love.   

Abstract

7 of 8 dogs receiving combination drug therapy consisting of flucytosine together with amphotericin B and/or a triazole for cryptococcosis or aspergillosis developed cutaneous or mucocutaneous eruptions during the course of treatment. Lesions resolved in all cases following discontinuation of flucytosine despite continued administration of other antifungals, suggesting the eruption was referable primarily to the flucytosine component of therapy. Lesions developed 13 to 41 days (median 20 days) after commencing flucytosine (105 to 188 mg/kg/day divided and given every 8 h; median dose rate 150 mg/kg/day). The cumulative dose of flucytosine given prior to the first signs of the drug eruption ranged from 1.7 to 6.8 g/kg (median 2.3 g/kg). The eruptions consisted of depigmentation, followed by ulceration, exudation and crust formation. The scrotum was affected in all 4 male dogs, the nasal plane in 6 of 7 cases, while the lips, vulva, external ear canal and integument were involved in a smaller number of cases. There was considerable variation in the severity of lesions, with changes being most marked when flucytosine was continued for several days after lesions first appeared. Some dogs experienced malaise and inappetence in association with the suspected drug eruption. Healing took a variable period, typically in excess of 2 weeks after discontinuing flucytosine, with up to 2 months being required for total resolution of the lesions. All lesions resolved eventually without scarring or permanent loss of pigment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8937669     DOI: 10.1111/j.1751-0813.1996.tb13776.x

Source DB:  PubMed          Journal:  Aust Vet J        ISSN: 0005-0423            Impact factor:   1.281


  3 in total

1.  Antifungal drug susceptibility and phylogenetic diversity among Cryptococcus isolates from dogs and cats in North America.

Authors:  Lisa M Singer; Wieland Meyer; Carolina Firacative; George R Thompson; Eileen Samitz; Jane E Sykes
Journal:  J Clin Microbiol       Date:  2014-04-02       Impact factor: 5.948

2.  Pharmacokinetics and tolerance of repeated oral administration of 5-fluorocytosine in healthy dogs.

Authors:  Jérémy Béguin; Matthias Kohlhauer; Eve Laloy; Frédérique Degorce; Baptiste Moreau; Éric Quéméneur; Philippe Erbs; Bernard Klonjkowski; Christelle Maurey
Journal:  BMC Vet Res       Date:  2021-06-21       Impact factor: 2.741

3.  Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs.

Authors:  Jérémy Béguin; Virginie Nourtier; Murielle Gantzer; Sandrine Cochin; Johann Foloppe; Jean-Marc Balloul; Eve Laloy; Dominique Tierny; Bernard Klonjkowski; Eric Quemeneur; Christelle Maurey; Philippe Erbs
Journal:  BMC Vet Res       Date:  2020-08-25       Impact factor: 2.741

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.